These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 10856096

  • 1. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
    Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC.
    J Clin Oncol; 2000 Jun; 18(12):2369-77. PubMed ID: 10856096
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
    Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC.
    J Clin Oncol; 1999 Dec; 17(12):3828-34. PubMed ID: 10577856
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
    Khayat D, Chollet P, Antoine EC, Monfardini S, Ambrosini G, Benhammouda A, Mazen MF, Sorio R, Borg-Olivier O, Riva A, Ramazeilles C, Azli N.
    J Clin Oncol; 2001 Jul 15; 19(14):3367-75. PubMed ID: 11454884
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
    Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF.
    J Clin Oncol; 1999 May 15; 17(5):1435-41. PubMed ID: 10334528
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C, Giannopoulos A, Kalahanis N, Stamatiadis D, Kouraklis G, Karatzas G, Liapis C, Syrigos K.
    Anticancer Res; 2003 May 15; 23(3C):2917-23. PubMed ID: 12926135
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
    Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, Kovats E, Lang F, Schneeweiss B, Scheithauer W.
    J Clin Oncol; 2001 Feb 01; 19(3):621-7. PubMed ID: 11157011
    [Abstract] [Full Text] [Related]

  • 17. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
    Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, Schunemann H, Kalakun L, Koya R, Pohlman P, Venegas LF.
    Oncology (Williston Park); 1997 Apr 01; 11(4 Suppl 3):24-9. PubMed ID: 9144687
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
    Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ.
    J Clin Oncol; 1999 Mar 01; 17(3):880-6. PubMed ID: 10071279
    [Abstract] [Full Text] [Related]

  • 20. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A, Spanish Breast Cancer Research Group.
    J Clin Oncol; 2004 Jul 01; 22(13):2587-93. PubMed ID: 15226326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.